Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

Gilead takes stake in Tango, expands 2018 deal
Gilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango Therapeutics Inc. to cover worldwide options over seven years from five to 15 immuno-oncology targets in exchange for $125 million up front and a $20 million equity investment. Tango is eligible for up to $410 million per program in opt-in, extension and milestone payments, plus low double-digit tiered royalties. Tango may co-promote and co-develop up to five programs in the U.S. (see “Tango, Gilead Partner”).

Roche’s Enspryng gains FDA approval
FDA approved Enspryng satralizumab-mwge from Roche (SIX:ROG; OTCQX:RHHBY) to treat neuromyelitis optica spectrum disorder patients positive for anti-AQP4 antibodies. In two weeks, the pharma will launch the mAb against IL-6R, which patients or trained caregivers can subcutaneously administer at home...